parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in pituitary stem cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	9 Parkinson's papers of 306	0.70
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 4798

receipt 4807: NRCAM in dopamine neurons, braak

power: full sample +0.09 (p 0.735, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.579, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.715, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.23, sign flips 1; without severely affected donors +0.09 (p 0.735, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NRCAM in dopamine neurons.

case closed: nothing better to follow up.

receipt 4806: NRCAM in oligodendrocytes, braak

power: full sample -0.20 (p 0.429, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.465, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
skeptic: leave-one-out range -0.34 to -0.09, sign flips 0; without severely affected donors -0.20 (p 0.429, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NRCAM in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts